Antonio Frassoldati

Antonio Frassoldati

Auto-generated profile, based on publicly available information

Antonio Frassoldati

Clinical Oncology, Department of Translational Medicine and for Romagna, S. Anna University Hospital, Ferrara, Italy

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
VGValentina Guarneri
Valentina Guarneri
AFAntonio Frassoldati
Antonio Frassoldati
ABAlberto Bottini
Alberto Bottini
KCKatia Cagossi
Katia Cagossi
GBGiancarlo Bisagni
Giancarlo Bisagni
Pierfranco ContePierfranco Conte
Pierfranco Conte
Purpose: This is a noncomparative, randomized, phase II trial of preoperative taxane-anthracycline in combination with trastuzumab, lapatinib, or combined trastuzumab plus lapatinib in patients with human epidermal growth factor receptor 2 (HER2) –positive, stage II to IIIA operable breast cancer. The primary aim was to estimate the percentage of pathologic complete response (pCR; no invasive tumor in breast and axillary nodes). Patients and Methods: In the three arms, chemotherapy consisted of weekly paclitaxel (80 mg/m2) for 12 weeks followed by fluorouracil, epirubicin, and cyclophosphamide for four courses every 3 weeks. The patients randomly assigned to arm A received a 4-mg loading dose of trastuzumab followed by 2 mg weekly; in arm B patients received lapatinib 1,500 mg orally (PO) daily; and in arm C, patients received trastuzumab and lapatinib 1,000 mg PO daily. Results: A total of 121 patients were randomly assigned. Diarrhea and dermatologic and hepatic toxicities were observed more frequently in patients receiving lapatinib. No episodes of congestive heart failure were observed. The rates of breast-conserving surgery were 66.7%, 57.9%, and 68.9% in arms A, B and C, respectively. The pCR rates were 25% (90% CI, 13.1% to 36.9%) in arm A, 26.3% (90% CI, 14.5% to 38.1%) in arm B, and 46.7% (90% CI, 34.4% to 58.9%) in arm C (exploratory P = .019). Conclusion: The primary end point of the study was met, with a relative increase of 80% in the pCR rate achieved with chemotherapy plus trastuzumab and lapatinib compared with chemotherapy plus either trastuzumab or lapatinib. These data add further evidence supporting the superiority of a dual-HER2 inhibition for the treatment of HER2-positive breast cancer.

9 October 2012 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
RCRobert Coleman
Robert Coleman
RBR. de Boer
R. de Boer
HEH. Eidtmann
H. Eidtmann
ALA. Llombart
A. Llombart
NDN. Davidson
N. Davidson
NBN. Bundred
N. Bundred
Aromatase inhibitors are the preferred adjuvant endocrine therapy for the majority of postmenopausal women with hormone-responsive early breast cancer. Although generally more effective than tamoxifen, aromatase inhibitor therapy is associated with increased bone loss and fracture risk. Postmenopausal women receiving adjuvant letrozole (2.5 mg/day for 5 years; N = 1065) were randomly assigned to immediate zoledronic acid (zoledronate) 4 mg every 6 months for 5 years, or delayed zoledronate (initiated for fracture or on-study bone mineral density [BMD] decrease). The primary end point was the change in lumbar spine BMD at 12 months. Lumbar spine and total hip BMD at subsequent follow-up, disease-free survival (DFS), and overall survival were assessed as secondary end points. At 60 months (final analysis), the mean change in lumbar spine BMD was +4.3% with immediate zoledronate and −5.4% with delayed intervention (P < 0.0001). Immediate zoledronate reduced the risk of DFS events by 34% (hazard ratio [HR] = 0.66; P = 0.0375) with fewer local (0.9% versus 2.3%) and distant (5.5% versus 7.7%) recurrences versus delayed zoledronate. In the delayed group, delayed initiation of zoledronate substantially improved DFS versus no zoledronate (HR = 0.46; P = 0.0334). Immediate zoledronate in postmenopausal women receiving letrozole preserved BMD and is associated with improved DFS compared with letrozole alone. NCT00171340.

28 April 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
GGGiulia Grisendi
Giulia Grisendi
RBRita Bussolari
Rita Bussolari
LCLuigi Cafarelli
Luigi Cafarelli
IPIstvan Petak
Istvan Petak
VRValeria Rasini
Valeria Rasini
MDMassimo Dominici
Massimo Dominici
Adipose-derived mesenchymal stromal/stem cells (AD-MSC) may offer efficient tools for cell-based gene therapy approaches. In this study, we evaluated whether AD-MSC could deliver proapoptotic molecules for cancer treatment. Human AD-MSCs were isolated and transduced with a retroviral vector encoding full-length human tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), a proapoptotic ligand that induces apoptosis in a variety of human cancers but not normal tissues. Although several studies have documented the antitumor activity of recombinant human TRAIL, its use in vivo is limited by a short half-life in plasma due to a rapid clearance by the kidney. We found that these limitations can be overcome using stably transduced AD-MSC, which could serve as a constant source of TRAIL production. AD-MSC armed with TRAIL targeted a variety of tumor cell lines in vitro, including human cervical carcinoma, pancreatic cancer, colon cancer, and, in combination with bortezomib, TRAIL-resistant breast cancer cells. Killing activity was associated with activation of caspase-8 as expected. When injected i.v. or s.c. into mice, AD-MSC armed with TRAIL localized into tumors and mediated apoptosis without significant apparent toxicities to normal tissues. Collectively, our results provide preclinical support for a model of TRAIL-based cancer therapy relying on the use of adipose-derived mesenchymal progenitors as cellular vectors. Cancer Res; 70(9); 3718–29. ©2010 AACR.

1 February 2012 in Clinical Breast Cancer
Verified
Journal Article
Closed access
ALANTONIO LLOMBART-CUSSAC
ANTONIO LLOMBART-CUSSAC
AFAntonio Frassoldati
Antonio Frassoldati
OPOuti Paija
Outi Paija
HSHarm Peter Sleeboom
Harm Peter Sleeboom
GJGuy Jerusalem
Guy Jerusalem
PNPatrick Neven
Patrick Neven

20 February 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MMMichela Maur
Michela Maur
CTChiara Tomasello
Chiara Tomasello
AFAntonio Frassoldati
Antonio Frassoldati
MDMaria Vittoria Dieci
Maria Vittoria Dieci
EBElena Barbieri
Elena Barbieri
Pierfranco ContePierfranco Conte
Pierfranco Conte
.....T his is the first case of PRES during ipilimumab therapy. Increasing awareness of PRES is needed in patients who undergo anti–CTLA-4 therapies and develop irAEs such as hypophysitis in our patient. Autoimmune disorders are associated with an increased risk of PRES; autoimmune hypophysitis, however, does not seem to be implicated in the development of PRES. Further inves-\ud tigations on the mechanisms of toxicity and risk factors for PRES are necessar

2 May 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
MFManuela Ferracin
Manuela Ferracin
LLLaura Lupini
Laura Lupini
ISIrene Salamon
Irene Salamon
ESElena Saccenti
Elena Saccenti
MZMaria Vittoria Zanzi
Maria Vittoria Zanzi
Massimo NegriniMassimo Negrini
Massimo Negrini
Absolute quantification of cell-free microRNAs in cancer patients Absolute quantification of cell-free microRNAs in cancer patients